|
|||||
|
|
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines |
|
| Affiliation: | 1. Global Healthcare Consulting, New Delhi, India;2. University of Washington, Seattle, WA, USA;3. International Vaccine Institute, Seoul, Republic of Korea;4. Janssen Pharmaceuticals, Titusville, NJ, USA;5. Independent Adviser, UK;6. International AIDS Vaccine Initiative, New York, NY, USA;7. Stanford School of Medicine, Palo Alto, CA, USA;8. Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL, USA;9. Independent Adviser, USA;10. Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA;11. Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany;12. Project Leader, CEPI, UK;13. University of Jordan, Amman, Jordan;14. Sanofi Pasteur, Swiftwater, PA, USA |
| Abstract: | Inactivated viral vaccines have long been used in humans for diseases of global health threat and are now among the vaccines for COVID-19 under development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of inactivated viral vaccines. This will help key stakeholders to assess potential safety issues and understand the benefit-risk of the vaccine platform. The standardized and structured assessment provided by the template would also help to contribute to improved communication and support public acceptance of licensed inactivated viral vaccines. |
| Keywords: | Brighton Collaboration CEPI COVID-19 Vaccine Benefit-risk Safety Inactivated Virus Template |
| 本文献已被 ScienceDirect 等数据库收录！ | |